Publicacións en colaboración con investigadores/as de Universitat de Barcelona (52)

2024

  1. Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)

    Vaccines, Vol. 12, Núm. 1

  2. Author Correction: Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium (npj Vaccines, (2024), 9, 1, (53), 10.1038/s41541-024-00838-8)

    npj Vaccines

  3. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

  4. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium

    Emerging Microbes and Infections, Vol. 13, Núm. 1

  5. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium

    npj Vaccines, Vol. 9, Núm. 1

  6. Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties

    Pharmaceutics, Vol. 16, Núm. 8

  7. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. A Randomized Trial of Dolutegravir Plus Darunavir/ Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes

    Open Forum Infectious Diseases, Vol. 10, Núm. 11

  2. A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery

    Molecules, Vol. 28, Núm. 24

  3. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs

    Biomedicine and Pharmacotherapy, Vol. 164

2022

  1. A New Family of Subnanomolar inhibitors of Soluble Epoxide Hydrolase

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36

  2. Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 236

  3. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4909-4925

  4. Insights into the Pharmacokinetics and In Vitro Cell‐Based Studies of the Imidazoline I2 Receptor Ligand B06

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  5. Soluble Epoxide Hydrolase Inhibitors: Design, Synthesis, in vitro Profiling and in vivo Evaluation in Murine Models of Pain

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36

  6. Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors

    Journal of medicinal chemistry, Vol. 65, Núm. 20, pp. 13660-13680

2021

  1. 2-(Piperidin-4-yl)acetamides as Potent Inhibitors of Soluble Epoxide Hydrolase with Anti-Inflammatory Activity

    Pharmaceuticals, Vol. 14, Núm. 12

  2. Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 222

  3. From the Design to the in Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

    Journal of Medicinal Chemistry, Vol. 64, Núm. 9, pp. 5429-5446

  4. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects

    European Journal of Medicinal Chemistry, Vol. 225